EA201490760A1 - R(+)-n-метилпропаргиламиноиндан - Google Patents

R(+)-n-метилпропаргиламиноиндан

Info

Publication number
EA201490760A1
EA201490760A1 EA201490760A EA201490760A EA201490760A1 EA 201490760 A1 EA201490760 A1 EA 201490760A1 EA 201490760 A EA201490760 A EA 201490760A EA 201490760 A EA201490760 A EA 201490760A EA 201490760 A1 EA201490760 A1 EA 201490760A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methylpropargylaminoindane
salt
rasagiline
validating
composition
Prior art date
Application number
EA201490760A
Other languages
English (en)
Inventor
Мухаммад Сафади
Антон Френкел
Михал Кейсар
Данит Лайт
Элизер Бахар
Рами Лидор-Хадас
Марина Жолковски
Рахель Коэн
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201490760A1 publication Critical patent/EA201490760A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

Изобретение представляет R(+)-N-метилпропаргиламиноиндан или его фармацевтически приемлемую соль и композицию, содержащую R(+)-N-пропаргил-1(R)-аминоиндан или его фармацевтически приемлемую соль и соединение R(+)-N-метилпропаргиламиноиндана или его соли. Также раскрыты способы валидации партии разагилина для применения в фармацевтическом составе и способ валидации состава разагилина для распределения, основанные на содержании R(+)-N-метилпропаргиламиноиндана или его соли.
EA201490760A 2011-10-10 2012-10-09 R(+)-n-метилпропаргиламиноиндан EA201490760A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161545426P 2011-10-10 2011-10-10
PCT/US2012/059358 WO2013055689A1 (en) 2011-10-10 2012-10-09 R(+)-n-methyl-propargyl-aminoindan

Publications (1)

Publication Number Publication Date
EA201490760A1 true EA201490760A1 (ru) 2014-09-30

Family

ID=48042233

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490760A EA201490760A1 (ru) 2011-10-10 2012-10-09 R(+)-n-метилпропаргиламиноиндан

Country Status (15)

Country Link
US (1) US9339469B2 (ru)
EP (1) EP2766004A4 (ru)
JP (1) JP2014534197A (ru)
KR (1) KR20140084153A (ru)
CN (1) CN103930100A (ru)
AR (1) AR088766A1 (ru)
AU (1) AU2012323351A1 (ru)
BR (1) BR112014008552A2 (ru)
CA (1) CA2851433A1 (ru)
EA (1) EA201490760A1 (ru)
HK (1) HK1200314A1 (ru)
IL (1) IL231722A0 (ru)
MX (1) MX2014004201A (ru)
WO (1) WO2013055689A1 (ru)
ZA (1) ZA201403050B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
MX2008012781A (es) * 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
ATE528989T1 (de) * 2006-12-14 2011-11-15 Teva Pharma Kristalline feste rasagilin-base
SG187455A1 (en) * 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
EP2451771B1 (en) 2009-07-09 2014-06-18 Ratiopharm GmbH Salts of rasagiline and pharmaceutical preparations thereof
US20110130466A1 (en) * 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
CN111983075A (zh) * 2020-08-17 2020-11-24 重庆华森制药股份有限公司 一种检测雷沙吉兰及其对映异构体的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL112819A (en) 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP1535902B1 (en) 1996-12-18 2007-11-07 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
SI1567152T1 (sl) 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20060018957A1 (en) 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
NZ560660A (en) 2005-02-23 2010-11-26 Teva Pharma Rasagiline ( R(+)-N-propargyl-1-aminodan ) formulations of improved content uniformity
JP2009521402A (ja) 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
MX2008012781A (es) 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PL2101570T3 (pl) 2006-12-14 2013-07-31 Teva Pharma Sól taninianu rasagiliny
ATE528989T1 (de) 2006-12-14 2011-11-15 Teva Pharma Kristalline feste rasagilin-base
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
SG187455A1 (en) 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
WO2009151594A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
EP2296462A4 (en) 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON
WO2009154782A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
EA021472B1 (ru) 2008-06-19 2015-06-30 Тева Фармасьютикал Индастриз, Лтд. Способ получения и сушки твердого разагилина в форме основания
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
EP2451771B1 (en) 2009-07-09 2014-06-18 Ratiopharm GmbH Salts of rasagiline and pharmaceutical preparations thereof
US20110130466A1 (en) 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
US8569379B2 (en) 2010-07-27 2013-10-29 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
KR20140023872A (ko) 2010-10-26 2014-02-27 테바 파마슈티컬 인더스트리즈 리미티드 중수소 농축 라사길린
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
MX2014004196A (es) 2011-10-10 2014-05-28 Teva Pharma Citramida de rasagilina.
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline

Also Published As

Publication number Publication date
WO2013055689A1 (en) 2013-04-18
US9339469B2 (en) 2016-05-17
EP2766004A4 (en) 2015-04-22
MX2014004201A (es) 2015-01-12
CN103930100A (zh) 2014-07-16
US20130089610A1 (en) 2013-04-11
EP2766004A1 (en) 2014-08-20
AU2012323351A1 (en) 2014-05-22
AR088766A1 (es) 2014-07-02
BR112014008552A2 (pt) 2017-04-18
ZA201403050B (en) 2015-08-26
JP2014534197A (ja) 2014-12-18
WO2013055689A8 (en) 2014-04-10
IL231722A0 (en) 2014-05-28
HK1200314A1 (en) 2015-08-07
CA2851433A1 (en) 2013-04-18
KR20140084153A (ko) 2014-07-04

Similar Documents

Publication Publication Date Title
EA201490760A1 (ru) R(+)-n-метилпропаргиламиноиндан
MX2020005446A (es) Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
EA201490756A1 (ru) Разагилина цитрамид
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
GB201118656D0 (en) New compounds
IN2014DN10670A (ru)
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
PH12014501991B1 (en) Phenicol antibacterials
NZ721952A (en) Delayed release compositions of linaclotide
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
EA201492029A1 (ru) N-этил-4-гидроксил-1-метил-5-(метил(2,3,4,5,6-пентагидроксигексил)амино)-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
PH12014502407A1 (en) New alfentanil composition for the treatment of acute pain
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
MX356102B (es) Compuestos y métodos para tratar leucemia.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.